CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Thomas Jefferson University
M.D. Anderson Cancer Center
Lyell Immunopharma, Inc.
Ohio State University Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
AIDS Malignancy Consortium
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Gilead Sciences
Affiliated Hospital to Academy of Military Medical Sciences
Masonic Cancer Center, University of Minnesota
Hackensack Meridian Health
Artiva Biotherapeutics, Inc.
University Hospital, Caen
AvenCell Therapeutics, Inc.
Stanford University
St. Jude Children's Research Hospital
Memorial Sloan Kettering Cancer Center
Medical University of South Carolina
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Baylor College of Medicine
Fred Hutchinson Cancer Center
Fate Therapeutics
Gilead Sciences
City of Hope Medical Center
Center for International Blood and Marrow Transplant Research
M.D. Anderson Cancer Center
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Allogene Therapeutics
Merck Sharp & Dohme LLC
Massachusetts General Hospital
Chinese PLA General Hospital
Memorial Sloan Kettering Cancer Center
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Gilead Sciences
Allogene Therapeutics
Hoffmann-La Roche
Baptist Health South Florida
Malaghan Institute of Medical Research
Allogene Therapeutics
Allogene Therapeutics
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center